Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-20

Study Completion Date

2023-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to explore the clinical and immunological efficacy of tofacitinib on primary Sjögren's Syndrome

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome

NCT04496960

Sjogren's Syndrome

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease

NCT07281456

Sjogren's Syndrome

RECRUITING PHASE2

Clinical Cohort Study in Patients With Different Subtypes of Primary Sjogren Syndrome Related Dry Eye

NCT05605314

Dry Eye

RECRUITING

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

NCT05946941

Sjögren's Syndrome

RECRUITING PHASE3

Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients

NCT04605978

Primary Sjögren's Syndrome

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators designed a single center, open-label, prospective study. Adults with active primary Sjögren's Syndrome will be enrolled, meeting the American College of Rheumatology(ACR) \& European allance of associations for rheumatology(EULAR)(2016) diagnostic criteria . Tofacitinib 5 mg bd was administered for 6 months to explore its efficacy and safety. The improvement of clinical and laboratory indexes was evaluated. Changes of immune cell subsets and cytokines were monitored.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Sjögren's Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

tofacitinib

Tofacitinib 5mg was taken orally twice a day for 6 months

Group Type EXPERIMENTAL

Tofacitinib

Intervention Type DRUG

Tofacitinib 5mg was taken orally twice a day for 6 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tofacitinib

Tofacitinib 5mg was taken orally twice a day for 6 months

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female \>18 years of age at screening visits
2. Patients meet the American-European Consensus Group 2002 classification criteria
3. The patient must be informed in writing of the consent to participate in the trial and the patient is expected to be able to comply with the requirements of the study follow-up plan and other protocols.
4. Dosing of antimalarials, prednisone or equivalent, cholinergic stimulants, and topical cyclosporine required to be stable for at least 4 weeks before screening and during study; maximum doses allowed:

* Hydroxychloroquinone, 400 mg/day;
* Prednisone, 10 mg/day

Exclusion Criteria

Any subject meeting any of the following criteria should be excluded:

1. Laboratory abnormality:

* Hb≤9 g/dl
* Neutrophil \<1.0 x 109/l
* lymphocyte\<0.5 x 109/l
2. Diagnosis of other autoimmune disease, or other sicca syndrome.
3. Use rituximab or other monoclonal antibodies within 6 months.
4. Received high doses of glucocorticoid (\>10 mg/d) within 1 month.
5. Serious complications: including heart failure (≥ New York Heart Association (NYHA) class III), renal insufficiency (creatinine clearance ≤ 30 ml/min), liver dysfunction (serum Alanine transaminase (ALT) or aspartate aminotransferase (AST) greater than three times the upper limit of normal, or total bilirubin greater than Normal upper limit)
6. Known allergies, hyperreactivity or intolerance of tofacitinib or its excipients.
7. Have a serious infection needing hospitalization (including but not limited to hepatitis, pneumonia, bacteremia, pyelonephritis, EB virus, tuberculosis infection), or use intravenous antibiotics to treat infection in 2 months before the enrollment.
8. Infection with HIV (HIV antibody positive serology) or hepatitis C (Hep C antibody positive serology). If seropositive, it is recommended to consult a doctor who has expertise in treating HIV or hepatitis C virus infection.
9. Any known history of malignancy in the past 5 years (except for non-melanoma skin cancer, non-melanoma skin cancer or cervical tumor without recurrence within 3 months after surgical cure prior to the first study preparation).
10. Uncontrolled mental or emotional disorders, including a history of drug and alcohol abuse over the past 3 years, may hinder the successful completion of the study.
11. Pregnant, lactating women (WCBP) are reluctant to use medically approved contraceptives during treatment and 12 months after treatment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No